Track market-moving stories before they get noisy

Boston Scientific (BSX.N) said on Tuesday it no longer expects to meet ​its previously issued third-quarter and full-year 2026 sales and adjusted profit ‌forecasts, after a cybersecurity incident disrupted the medical device maker's global operations.

An unauthorized activity on some of its information technology systems, first identified on August 25, caused a network outage that disrupted manufacturing ​and the processing and shipment of customer orders, the company said in ​a regulatory filing.

Stifel analyst Rick Wise said investors increasingly view 2026 as ⁠a "lost year" for Boston Scientific and are likely to focus more on the ​company's prospects for 2027.

Shares of the company were down 2.3% in morning trading.

In July, ​Boston Scientific had forecast 2026 adjusted earnings of $3.28 to $3.32 per share and sales growth of 5.5% to 6.5% on a reported basis. For the third quarter, it had projected adjusted earnings of 80 ​cents to 82 cents per share.

It expects to recover a portion of the affected ​revenue as it ramps up operations and works through backlogs, but said the full financial impact ‌remains ⁠uncertain.

The incident is the latest in a series of cyberattacks on the healthcare sector, with medical device makers Abbott Laboratories (ABT.N), Stryker (SYK.N) and Medtronic (MDT.N) and drugmaker Novo Nordisk (NOVOb.CO) among those recently hit.

In an update on Saturday, Boston Scientific said that the incident's effects were ​limited to select internal ​infrastructure and that ⁠product quality analyses found no impairment beyond disruptions to new activations of its cardiac device remote-monitoring platform.

J.P.Morgan analyst Robbie Marcus said ​the cyberattack clouds visibility into Boston Scientific's underlying business trends, ​delaying investors' ⁠ability to assess growth and competitive dynamics in key franchises, including electrophysiology and heart device Watchman.

The company said major distribution centers are now processing and shipping orders at or ⁠above normal ​levels, sterilization facilities are operational, and manufacturing has ​resumed across most facilities globally.

Boston Scientific plans to provide an updated outlook when it reports third-quarter results on ​October 28.

Key Takeaways BSX faces an uncertain cyberattack impact amid disruptions to manufacturing and customer order processing.BSX lowered 2026 guidance as WATCHMAN and Electrophysiology face unexpected headwinds.BSX has plunged 49.1% YTD, trades below key SMAs and carries a premium to its industry. Boston Scientific (BSX - Free Report) , the Marlborough-based medical device maker, is navigating a challenging period. On Aug. 25, the company disclosed a cybersecurity incident that affected access to certain operating systems and business applications, including its ability to manufacture products, as well as process and ship customer orders.

Once detected, Boston Scientific activated its incident response protocols and launched an investigation with the help of CrowdStrike and other third-party experts. The company is working to restore affected operations, but the timeline for full recovery and the financial impact remain uncertain. The incident also comes amid a series of recent cybersecurity incidents across the medical device industry. BSX’s peer Abbott (ABT - Free Report) faced a cyber incident in July that impacted a limited number of internal systems in its Cancer Diagnostics business, while Medtronic (MDT - Free Report) faced a cyber issue in April that impacted a few of its corporate IT systems.

Adding to the pressure, the latest development comes on top of a weaker annual outlook issued during the second-quarter earnings call in late July. Despite beating top- and bottom-line estimates, Boston Scientific lowered its full-year 2026 organic sales guidance to 5-6% and adjusted earnings per share (EPS) guidance to $3.28-$3.32. Foreign exchange is expected to create a roughly $0.05 headwind to the bottom line. Full-year adjusted gross margin is also projected to fall from the 2025 levels, largely due to unexpected headwinds within two high-growth franchises, WATCHMAN and Electrophysiology (“EP”).

BSX Stock Price PerformanceYear to date, shares of Boston Scientific have plunged 49.1% compared with its industry’s 17% decline and the Medical sector’s 4.2% growth. The S&P 500 composite has risen 10.8% during the period. BSX has also significantly trailed both Abbott and Medtronic, whose shares have dropped 11.8% and 4%, respectively, during the same period.

Image Source: Zacks Investment Research

BSX’s Technical IndicatorsThe following chart also shows that BSX is currently trading below its 90- and 200-day simple moving averages (SMAs), pointing to continued bearish momentum.

Image Source: Zacks Investment Research

Factors Impacting Boston ScientificSluggish Recovery in Urology: The Urology business within the company’s MedSurg segment fell short of internal expectations, growing just 1% in the second quarter of 2026. The weakness stemmed from underperformance in the stone management franchise due to volume-based procurement in China, and some key product gaps in the core stone portfolio. Sacral neuromodulation also continued to see the impact of commercial model disruption. Management now expects full-year Urology growth to be flat to low-single digits.

CRM’s Portfolio Gaps: Boston Scientific’s Cardiac Rhythm Management (“CRM”) continued to face pressure, with sales down 2% in the second quarter. The core business saw a high-single-digit decline in low-voltage products and a mid-single-digit decline in high-voltage products. Competitive pressures and gaps in the company’s portfolio are adding to these challenges. Management expects growth in this division to be flat for 2026, with only modest improvement later in the year, supported by the full launch of EluPro.

WATCHMAN Demand Weakness: WATCHMAN’s U.S. market has slowed sharply and unexpectedly because of compounding clinical evidence regarding stroke risk in AF patients affecting referral patterns. The rapid uptake of concomitant procedures has also created operational inefficiencies, making it difficult to sustain growth. Against this backdrop, Boston Scientific now expects global WATCHMAN growth to be flat to low-single digits in 2026, with the second-half growth declining mid- to high-single digits on a year-over-year basis. Third-quarter U.S. sales are projected to decline sequentially, while concomitant growth is also expected to slow materially in the second half due to tougher comparisons with 2025.

Rising Competition Hits Electrophysiology: Boston Scientific is facing an unanticipated degree of competitive share movement in the U.S. EP market. The rapid adoption of the FARAPULSE technology has pushed U.S. pulsed field ablation revenues to approximately 80% of the atrial fibrillation market. With this faster-than-anticipated penetration, the company’s ability to offset some competitive pressures has become limited. Management has adjusted its market share assumptions to reflect these developments and now expects global Electrophysiology growth to be flat in the second half of 2026. U.S. sales in the third quarter are expected to decline in the mid-single digits sequentially.

As shown below, estimates for BSX’s 2026 and 2027 earnings have been steadily revised downward.

Image Source: Zacks Investment Research

BSX’s ValuationBoston Scientific currently trades at a forward price/sale (P/S) of 3.17X over the past 12 months, below its median of 4.77X but above the industry average of 2.23X. The stock sits with a Value Score of C.

Image Source: Zacks Investment Research

EndnoteBoston Scientific is yet to fully assess the financial consequences of the cybersecurity incident, if any, that has disrupted its global operations. The company is also dealing with several other challenges across its businesses, including weaker U.S. demand in WATCHMAN and portfolio gaps within CRM. The lowered full-year 2026 financial outlook further reflects these pressures.  So far this year, BSX has been a major underperformer compared to its benchmarks and key peers. Although trading below its historical median, the stock still carries a premium to the industry. The company’s earnings outlook has also continued to slide in recent months. Given all these factors, current BSX holders should consider exiting their positions. 

Boston Scientific carries a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It has been about a month since the last earnings report for Boston Scientific (BSX - Free Report) . Shares have added about 1.5% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

BSX Q2 Earnings and Revenues Top EstimatesBoston Scientific reported second-quarter 2026 adjusted earnings of 86 cents per share, up 14.7% year over year. The figure beat the Zacks Consensus Estimate by 3.6%.

Revenues rose 7.5% on a reported basis to $5.44 billion and surpassed the consensus estimate by 1.1%. Cardiovascular growth, double-digit gains in Asia-Pacific (APAC) and Latin America and Canada (LACA) and strong Neuromodulation sales supported the quarter.

Segmental Results Reflect Broad-Based GrowthCardiovascular revenues totaled $3.62 billion, increasing 8.3% on a reported basis and 7.8% on an operational and organic basis. The segment generated roughly two-thirds of Boston Scientific’s quarterly revenues and remained the primary growth contributor.

MedSurg revenues rose 5.9% to $1.82 billion, with operational and organic growth of 5.4%. Within the segment, Endoscopy sales increased 7.6% to $793 million, while Neuromodulation revenues climbed 12.7% to $341 million. Urology revenues advanced 1.1% to $684 million, marking the slowest growth among the company’s reported businesses.

Broad Regional Sales GainsU.S. revenues increased 6.2% to $3.43 billion. The domestic market remained Boston Scientific’s largest region, generating nearly 63% of consolidated sales.

APAC revenues rose 11.2% to $878 million, while LACA sales surged 22.4% to $206 million. LACA operational growth was 16.2%. Europe, Middle East and Africa (“EMEA”) revenues increased 6.1% to $932 million, although operational growth was lower at 4.2% due to currency effects.

Boston Scientific Expands Quarterly MarginsThe gross margin expanded approximately 306 basis points (bps) year over year to 70.7%. The cost of products sold declined 2.6% to $1.59 billion in the reported quarter.

Selling, general and administrative expenses rose 5.1% to $1.80 billion. Research and development expenses increased 5.3% to $554 million, while royalty expenses plunged 14.3% to $12 million. Adjusted operating margin expanded approximately 71 bps to 28.4%.

BSX Advances Its Cardiovascular PipelineBoston Scientific presented data from the FRACTURE trial of the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The study met its primary endpoints, demonstrating procedural success and high freedom from major adverse cardiac events at 30 days.

The AVANT GUARD study also met its safety and effectiveness endpoints. FARAPULSE pulsed field ablation demonstrated statistical superiority over anti-arrhythmic drugs in patients with persistent atrial fibrillation who had not received prior treatment for the condition.

New Growth InvestmentsThe company invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire its transcatheter aortic valve replacement business. MiRus is developing the investigational SIEGEL balloon-expandable TAVR system.

BSX also completed its previously announced $2 billion accelerated share repurchase program. The transaction resulted in the repurchase of approximately 40 million shares, reducing the company’s outstanding share base.

Q3 and Full-Year GuidanceBoston Scientific now expects reported sales growth of 5.5-6.5%, down from its prior forecast of 7-8.5%. Organic sales growth is now projected at 5-6% compared with the earlier range of 6.5-8%. 

The company also reduced its full-year adjusted earnings forecast to $3.28-$3.32 per share from the earlier $3.34-$3.41. 

For the third quarter, management forecasts reported and organic sales growth of 3-5%. Adjusted earnings are expected between 80 cents and 82 cents per share. 

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.

VGM ScoresCurrently, Boston Scientific has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock has a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Boston Scientific has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.

Performance of an Industry PlayerBoston Scientific belongs to the Zacks Medical - Products industry. Another stock from the same industry, Royal Philips (PHG - Free Report) , has gained 1.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Philips reported revenues of $5.07 billion in the last reported quarter, representing a year-over-year change of +3%. EPS of $0.57 for the same period compares with $0.41 a year ago.

Philips is expected to post break-even earnings per share for the current quarter, representing a year-over-year change of 0%. Over the last 30 days, the Zacks Consensus Estimate has changed 0%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Philips. Also, the stock has a VGM Score of A.

Aurora Investment Counsel bought a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 43,857 shares of the medical equipment provider’s stock, valued at approximately $1,872,000.

A number of other institutional investors have also recently made changes to their positions in BSX. Kelleher Financial Advisors bought a new position in Boston Scientific in the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific during the first quarter valued at $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last three months. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Up 3.1% BSX stock opened at $52.02 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The business has a 50 day simple moving average of $46.22 and a two-hundred day simple moving average of $58.22. The company has a market capitalization of $75.39 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.10 and a beta of 0.56. Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the business posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades BSX has been the topic of a number of recent analyst reports. Needham & Company LLC dropped their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Oppenheimer lowered their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, July 27th. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Finally, Raymond James Financial reissued an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Get Our Latest Research Report on Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Featured Articles Five stocks we like better than Boston Scientific Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Boston Scientific cut 2026 organic growth guidance to 5%-6% and lowered adjusted EPS guidance.WATCHMAN demand weakened, while U.S. electrophysiology share losses added near-term pressure.Debt rose to about $12.62 billion, and key recovery products are not expected before late 2027. Boston Scientific Corporation (BSX - Free Report) retains durable medical-device franchises, but its investment case has become harder to defend. Management lowered its 2026 outlook as WATCHMAN demand weakened, U.S. electrophysiology lost share and operating leverage fell short.

The stock’s valuation has compressed, creating potential upside if execution improves. Yet limited earnings visibility through 2027, higher debt and delayed product catalysts suggest investors may be better served by waiting for clearer signs of stabilization.

Why Boston Scientific’s Growth Outlook Has WeakenedBoston Scientific cut its 2026 organic sales growth guidance to 5%-6% from 6.5%-8%. Adjusted earnings guidance fell to $3.28-$3.32 per share from $3.34-$3.41, while third-quarter organic growth is expected at 3%-5%.

Here's where the consensus estimates for the company's 2026 earnings currently stand.

Image Source: Zacks Investment Research

The company now anticipates only 0-25 basis points of adjusted operating-margin expansion in 2026. Lower WATCHMAN and electrophysiology sales are hurting product mix, and elevated supply-chain and quality-system spending remains a drag. Management expects revenue growth below its weighted-average market rate and limited adjusted earnings growth in 2027.

BSX Faces Pressure in WATCHMAN and ElectrophysiologyU.S. WATCHMAN demand slowed as new clinical evidence disrupted patient identification and referral patterns. Standalone procedures declined at a low-teens rate in the second quarter, while management expects global WATCHMAN sales to fall at a mid- to high-single-digit rate in the second half of 2026.

Electrophysiology presents another near-term challenge. U.S. share losses exceeded expectations, and the existing FARAPULSE portfolio may not offset the pressure now that pulsed-field ablation represents about 80% of the U.S. atrial fibrillation market. Medtronic plc (MDT - Free Report) is expanding its Affera and PulseSelect pulsed-field ablation offerings, while Johnson & Johnson (JNJ - Free Report) is advancing its VARIPULSE platform, underscoring the competitive intensity confronting Boston Scientific’s FARAPULSE franchise.

Boston Scientific Still Has Durable Growth EnginesThe broader portfolio remains resilient. Second-quarter organic sales rose 12.2% in Neuromodulation and 7% in Endoscopy. International operations also provided support, with operational growth of 11.2% in Asia-Pacific and 16.2% in Latin America and Canada.

Interventional Cardiology, the FARAPULSE ecosystem, OPAL mapping, WATCHMAN FLX Pro and the wider pipeline could support longer-term growth. The Penumbra transaction and MiRus investment add vascular and structural-heart opportunities. Edwards Lifesciences Corporation (EW), whose transcatheter aortic valve replacement sales grew 11.3% in the second quarter of 2026, shows the scale of the structural-heart market Boston Scientific hopes to re-enter.

BSX Valuation Reflects Both Damage and UncertaintyBSX trades at 14.6X forward 12-month earnings, below its five-year median of 25.2X, the Medical-Products sub-industry’s 17.3X and the broader sector’s 20.6X. That discount could reward investors if growth and margins recover.

Image Source: Zacks Investment Research

The lower multiple also reflects material uncertainty. Earnings estimates have moved down, key recovery products are not expected until the second half of 2027 or later and execution remains critical. Cash fell to $539 million at the end of the second quarter, while total debt increased to about $12.62 billion.

Why BSX's Bearish Signals Still MatterThe balance of evidence favors patience rather than an aggressive purchase. Boston Scientific has valuable franchises and a credible pipeline, but weaker guidance, competitive gaps and delayed catalysts leave little room for execution errors.

BSX currently carries a Zacks Rank #5 (Strong Sell), indicating an unfavorable earnings-estimate revision trend over the next one to three months. Its Value Score of C, Growth Score of C, Momentum Score of C and VGM Score of C provide no strong style-based counterweight. The valuation is cheaper, but the near-term risk-reward profile still supports waiting for better visibility.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

, /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago.

"Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."

Second quarter financial results and recent developments:

Reported net sales of $5.442 billion, representing an increase of 7.5 percent on a reported basis, compared to the company's guidance range of 5.5 to 7.5 percent; and 7.0 percent on an operational and organic basis, compared to the company's guidance range of 5 to 7 percent, all compared to the prior year period. Reported GAAP net income attributable to Boston Scientific common stockholders of $0.61 per share, and achieved adjusted EPS of $0.86 per share, compared to the guidance range of $0.82 to $0.84 per share. Achieved the following net sales growth in each reportable segment, compared to the prior year period: MedSurg: 5.9 percent reported, 5.4 percent operational and organic Cardiovascular: 8.3 percent reported, 7.8 percent operational and organic Achieved the following net sales growth in each region, compared to the prior year period: United States (U.S.): 6.2 percent reported and operational Europe, Middle East and Africa (EMEA): 6.1 percent reported and 4.2 percent operational Asia-Pacific (APAC): 11.2 percent reported and operational Latin America and Canada (LACA): 22.4 percent reported and 16.2 percent operational Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares. Invested $1.5 billion in MiRus LLC, which is developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, in return for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business.4 Presented late-breaking findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints with the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter, demonstrating high rates of freedom from major adverse cardiac events at 30 days as well as procedural success in patients with severely calcified coronary artery disease.4 Announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026 including: The AVANT GUARD study of FARAPULSE™ Pulsed Field Ablation (PFA) for the treatment of persistent atrial fibrillation (AF) in patients who had not previously been treated for their condition. Data met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness. The ELEVATE-PF feasibility study of the FARAFLEX™ Mapping and PFA Catheter — a novel large focal, high-density map-and-ablate catheter — in patients with paroxysmal and persistent AF. The trial demonstrated strong lesion durability validated by cardiac remapping, with no reported cases of pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke.4  Commenced enrollment in the pivotal FARADIGM clinical trial to evaluate the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter for treating patients with paroxysmal and persistent AF.4  Received U.S. Food and Drug Administration 510(k) clearance for the TruSelect™ 2.6 Microcatheter, expanding Boston Scientific's embolization portfolio with a device designed to provide physicians with a single solution for navigation and efficient embolic delivery during minimally invasive procedures. 1.

Operational net sales growth excludes the impact of foreign currency fluctuations.

2.

Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.

3.

Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.

4.

The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Net sales for the second quarter by business and region:

Increase/(Decrease)

          Three Months Ended          

          June 30,          

Reported
Basis

Impact of
Foreign
Currency
Fluctuations

Operational

 Basis

Impact of
Certain
Acquisitions
/Divestitures

Organic
Basis

(in millions)

2026

2025

   Endoscopy

$      793

$      737

7.6 %

(0.7) %

7.0 %

— %

7.0 %

   Urology

684

676

1.1 %

(0.3) %

0.8 %

— %

0.8 %

   Neuromodulation                                      

341

303

12.7 %

(0.6) %

12.2 %

— %

12.2 %

MedSurg

1,818

1,716

5.9 %

(0.5) %

5.4 %

— %

5.4 %

Cardiovascular

3,624

3,345

8.3 %

(0.6) %

7.8 %

— %

7.8 %

Net Sales

$    5,442

$    5,061

7.5 %

(0.5) %

7.0 %

— %

7.0 %

Increase/(Decrease)

          Three Months Ended          

          June 30,          

Reported
Basis

Impact of
Foreign
Currency
Fluctuations

Operational

 Basis

(in millions)

2026

2025

U.S.

$     3,426

$     3,224

6.2 %

— %

6.2 %

EMEA

932

878

6.1 %

(1.9) %

4.2 %

APAC

878

790

11.2 %

(0.0) %

11.2 %

LACA

206

169

22.4 %

(6.2) %

16.2 %

Net Sales

$    5,442

$    5,061

7.5 %

(0.5) %

7.0 %

Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not           
prepared in accordance with U.S. GAAP.

Guidance for Full Year and Third Quarter 2026

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.

The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to 5 percent on a reported and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.

The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the third quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Use of Non-GAAP Financial Information

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

CONTACT:

‌          

Media:

Chanel Hastings

Investors:

Lauren Tengler

508-382-0288 (office)

508-683-4479 (office)

Media Relations

Investor Relations

Boston Scientific Corporation

Boston Scientific Corporation

[email protected]

[email protected]

BOSTON SCIENTIFIC CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

          Three Months Ended          

          June 30,          

‌

          Six Months Ended          

          June 30,          

(in millions, except per share data)

2026

2025

2026

2025

Net sales

$      5,442

$      5,061

$     10,646

$      9,724

Cost of products sold (excluding amortization expense)

1,594

1,637

3,184

3,090

Gross profit

3,848

3,424

7,462

6,633

Operating expenses:

Selling, general and administrative expenses

1,803

1,716

3,583

3,312

Research and development expenses

554

526

1,069

969

Royalty expense

12

14

24

28

Amortization expense

233

225

466

444

Intangible asset impairment charges

—

46

—

46

Contingent consideration net expense (benefit)

(16)

(5)

(46)

0

Restructuring net charges (credits)

8

83

11

93

Litigation-related net charges (credits)

76

—

76

—

2,670

2,605

5,183

4,894

Operating income (loss)

1,178

819

2,279

1,740

Other income (expense):

Interest expense

(96)

(90)

(186)

(172)

Other, net

(23)

213

129

179

Income (loss) before income taxes

1,060

941

2,222

1,746

Income tax expense (benefit)

155

146

(21)

279

Net income (loss)

905

795

2,243

1,467

Net income (loss) attributable to noncontrolling interests

(2)

(2)

(4)

(4)

Net income (loss) attributable to Boston Scientific common stockholders                                        

$        907

$        797

$      2,247

$      1,471

Net income (loss) per common share - basic

$        0.62

$        0.54

$        1.52

$        0.99

Net income (loss) per common share - diluted

$        0.61

$        0.53

$        1.51

$        0.98

Weighted-average shares outstanding

Basic

1,470.2

1,479.9

1,477.6

1,478.5

Diluted

1,474.8

1,493.5

1,484.9

1,493.3

Amounts may not add due to rounding.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

Three Months Ended June 30, 2026

(in millions, except per share data)

Gross
Profit

Operating
Expenses

Operating
Income
(Loss)

Other
Income
(Expense)

Income
(Loss)
Before
Income
Taxes

Net
Income
(Loss)

Net Income
(Loss)
Attributable to
Noncontrolling
Interests

Net Income
(Loss)
Attributable to
Boston
Scientific
Common
Stockholders

Impact
per
Share

Reported

$   3,848

$   2,670

$   1,178

$    (118)

$   1,060

$     905

$           (2)

$          907

$   0.61

Non-GAAP adjustments:

Amortization expense

—

(233)

233

—

233

206

2

203

0.14

Acquisition/divestiture-related net
charges/credits

30

(61)

91

1

92

72

—

72

0.05

Restructuring and restructuring-related net
charges/credits

25

(16)

42

—

42

37

—

37

0.02

Litigation-related net charges/credits

—

(76)

76

—

76

60

—

60

0.04

Investment portfolio net losses/gains and
impairments

—

—

—

(2)

(2)

(2)

—

(2)

(0.00)

EU MDR implementation costs

4

(3)

7

—

7

6

—

6

0.00

IEEPA tariff refund

(83)

—

(83)

—

(83)

(77)

—

(77)

(0.05)

Deferred tax expenses/benefits

—

—

—

—

—

70

—

70

0.05

Adjusted

$   3,824

$   2,281

$   1,543

$    (120)

$   1,423

$   1,275

$            1

$        1,275

$   0.86

Three Months Ended June 30, 2025

(in millions, except per share data)

Gross
Profit

Operating
Expenses

Operating
Income
(Loss)

Other
Income
(Expense)

Income
(Loss)
Before
Income
Taxes

Net
Income
(Loss)

Net Income
(Loss)
Attributable to
Noncontrolling
Interests

Net Income
(Loss)
Attributable to
Boston
Scientific
Common
Stockholders

Impact
per
Share

Reported

$   3,424

$   2,605

$     819

$     122

$     941

$     795

$           (2)

$          797

$   0.53

Non-GAAP adjustments:

Amortization expense

—

(225)

225

—

225

193

2

191

0.13

Goodwill and other intangible asset impairment
charges

—

(46)

46

—

46

37

—

37

0.02

Acquisition/divestiture-related net
charges/credits

46

(92)

138

(230)

(92)

(92)

—

(92)

(0.06)

Restructuring and restructuring-related net
charges/credits

37

(124)

161

—

161

142

—

142

0.10

Investment portfolio net losses/gains and
impairments

—

—

—

(2)

(2)

(2)

—

(2)

(0.00)

EU MDR implementation costs

7

(3)

10

—

10

9

—

9

0.01

Deferred tax expenses/benefits

—

—

—

—

—

45

—

45

0.03

Discrete tax items

—

—

—

—

—

0

—

0

0.00

Adjusted

$   3,514

$   2,114

$   1,399

$    (110)

$   1,289

$   1,127

$            0

$        1,127

$   0.75

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

Amounts may not add due to rounding.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

Six Months Ended June 30, 2026

(in millions, except per share data)

Gross
Profit

Operating
Expenses

Operating
Income
(Loss)

Other
Income
(Expense)

Income
(Loss)
Before
Income
Taxes

Net
Income
(Loss)

Net Income
(Loss)
Attributable to
Noncontrolling
Interests

Net Income
(Loss)
Attributable to
Boston
Scientific
Common
Stockholders

Impact
per
Share

Reported

$   7,462

$   5,183

$   2,279

$     (57)

$   2,222

$   2,243

$           (4)

$        2,247

$   1.51

Non-GAAP adjustments:

Amortization expense

—

(466)

466

—

466

410

5

406

0.27

Acquisition/divestiture-related net
charges/credits

57

(118)

175

(36)

139

103

—

103

0.07

Restructuring and restructuring-related net
charges/credits

47

(29)

77

—

77

69

—

69

0.05

Litigation-related net charges/credits

—

(76)

76

—

76

60

—

60

0.04

Investment portfolio net losses/gains and
impairments

—

—

—

(139)

(139)

(106)

—

(106)

(0.07)

EU MDR implementation costs

9

(5)

14

—

14

12

—

12

0.01

IEEPA tariff refund

(83)

—

(83)

—

(83)

(77)

—

(77)

(0.05)

Deferred tax expenses/benefits

—

—

—

—

—

(250)

—

(250)

(0.17)

Adjusted

$   7,492

$   4,490

$   3,002

$    (232)

$   2,771

$   2,465

$            1

$        2,464

$   1.66

Six Months Ended June 30, 2025

(in millions, except per share data)

Gross
Profit

Operating
Expenses

Operating
Income
(Loss)

Other
Income
(Expense)

Income
(Loss)
Before
Income
Taxes

Net
Income
(Loss)

Net Income
(Loss)
Attributable to
Noncontrolling
Interests

Net Income
(Loss)
Attributable to
Boston
Scientific
Common
Stockholders

Impact
per
Share

Reported

$   6,633

$   4,894

$   1,740

$       6

$   1,746

$   1,467

$           (4)

$        1,471

$   0.98

Non-GAAP adjustments:

Amortization expense

—

(444)

444

—

444

383

4

378

0.25

Goodwill and other intangible asset impairment
charges

—

(46)

46

—

46

37

—

37

0.02

Acquisition/divestiture-related net
charges/credits

136

(150)

286

(229)

57

61

—

61

0.04

Restructuring and restructuring-related net charges/credits

61

(149)

210

—

210

184

—

184

0.12

Investment portfolio net losses/gains and
impairments

—

—

—

6

6

5

—

5

0.00

EU MDR implementation costs

15

(7)

23

—

23

19

—

19

0.01

Deferred tax expenses/benefits

—

—

—

—

—

91

—

91

0.06

Discrete tax items

—

—

—

—

—

0

—

0

0.00

Adjusted

$   6,846

$   4,097

$   2,749

$    (216)

$   2,533

$   2,249

$            1

$        2,248

$   1.51

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

Amounts may not add due to rounding.

BOSTON SCIENTIFIC CORPORATION

Q3 and FY 2026 GUIDANCE RECONCILIATIONS

(Unaudited)

Net Sales

‌

                    Q3 2026 Estimate                    

               Full Year 2026 Estimate               

(Low)

(High)

(Low)

(High)

Reported growth

3.0 %

5.0 %

5.5 %

6.5 %

Impact of foreign currency fluctuations

— %

— %

(0.5) %

(0.5) %

Operational growth

3.0 %

5.0 %

5.0 %

6.0 %

Impact of certain acquisitions/divestitures                                                              

— %

— %

— %

— %

Organic growth

3.0 %

5.0 %

5.0 %

6.0 %

Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits), discrete tax items and other charges (credits) as appropriate. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." In addition to the explanation below, please refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item:

Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, we may incur certain charges such as severance and other compensation-related charges, fixed asset write-offs, contract cancellations, facility shutdown costs, and inventory write-downs associated with discontinuations of significant product lines. These restructuring plans and activities are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Deferred tax expenses (benefits) - These amounts represent significant non-cash tax benefits arising from internal reorganizations or intra-entity asset transfers. The deferred tax effects related to the establishment and subsequent reversal of net deferred tax assets are excluded from management's assessment of operating performance used for making operating decisions and assessing performance. IEEPA tariff refund - This amount relates to the benefit recognized in connection with the recovery of previously incurred tariffs imposed under the International Emergency Economic Powers Act (IEEPA) recognized in Cost of products sold within our unaudited consolidated statements of operations. This amount is excluded from management's assessment of operating performance used for making operating decisions and assessing performance. The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

SOURCE Boston Scientific Corporation

Bank of Nova Scotia raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 15.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,303,011 shares of the medical equipment provider’s stock after acquiring an additional 308,930 shares during the quarter. Bank of Nova Scotia owned approximately 0.15% of Boston Scientific worth $144,515,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its stake in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp grew its holdings in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors grew its holdings in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth about $2,199,395,000. Finally, Morgan Stanley increased its position in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance Shares of BSX opened at $43.67 on Friday. The stock has a market capitalization of $64.90 billion, a P/E ratio of 18.27, a P/E/G ratio of 0.82 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company’s fifty day moving average is $47.37 and its two-hundred day moving average is $64.20.

Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter last year, the business earned $0.75 EPS. The business’s revenue was up 11.6% on a year-over-year basis. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.35 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth Several research analysts have commented on BSX shares. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Jefferies Financial Group reduced their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a research note on Thursday, April 23rd. Truist Financial lowered their price objective on shares of Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Finally, Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.84.

Check Out Our Latest Stock Report on Boston Scientific

Insider Activity at Boston Scientific In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile (Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Read More Five stocks we like better than Boston Scientific Premium Retail’s Stress Test Is Separating Winners From Losers D-Wave Quantum or a Quantum ETF: Which Is the Better Bet? GE Vernova Just Sent a Mixed AI Signal to Investors Alphabet Crushed Earnings, But One Number Spooked the Market

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

In the latest close session, Boston Scientific (BSX - Free Report) was down 1.2% at $44.60. The stock trailed the S&P 500, which registered a daily gain of 0.72%. On the other hand, the Dow registered a gain of 0.3%, and the technology-centric Nasdaq increased by 1.12%.

The medical device manufacturer's stock has dropped by 7.02% in the past month, falling short of the Medical sector's gain of 12.48% and the S&P 500's loss of 0.9%.

The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. The company is forecasted to report an EPS of $0.83, showcasing a 10.67% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $5.39 billion, reflecting a 6.54% rise from the equivalent quarter last year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.

Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.32% lower within the past month. Right now, Boston Scientific possesses a Zacks Rank of #4 (Sell).

In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 13.44. Its industry sports an average Forward P/E of 19.08, so one might conclude that Boston Scientific is trading at a discount comparatively.

We can additionally observe that BSX currently boasts a PEG ratio of 0.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry currently had an average PEG ratio of 1.73 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.